AstraZeneca sells 3 more drugs for $350 million

Nov 06, 2018

Following up on last week's $815 million sale, AstraZeneca is selling three older drugs for asthma and rhinitis for at least $350 million as the company continues its divestment strategy in order to shift its investment to new medicines.

Covis Pharma will pay AstraZeneca $350 million for rights to Alvesco, Omnaris and Zetonna, plus conditional sales-related payments of up to $21 million over four years from 2019. In 2017, the three drugs had combined sales of $106 million. Covis already markets the drugs in the United States.

According to the companies, the deal is expected to close by the end of 2018.

Read the Reuters report

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!